Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies. Review uri icon

Overview

abstract

  • Over the past decade, the ability of cancer cells to evade immune destruction has become recognized as one of the hallmarks of cancer. This understanding has paved the way for the development of novel therapeutic agents that can enhance activation of antitumor immune responses or reverse immunosuppressive mechanisms through which tumors escape immune-mediated rejection. The treatment of gynecologic cancers remains a therapeutic challenge, as these malignancies are often diagnosed in advanced stages, and many patients relapse despite appropriate management. Clinical trials have shown efficacy for various immunotherapeutic strategies, especially the use of tumor-targeting antibodies; enhancement of tumor antigen presentation, such as with vaccines and toll-like receptor agonists; and the targeting of immunosuppressive mechanisms, such as via checkpoint blockade. Emerging data on new and combination approaches currently under investigation provide a strong rationale for these approaches.

publication date

  • January 1, 2016

Research

keywords

  • Genital Neoplasms, Female
  • Immunotherapy

Identity

PubMed Central ID

  • PMC4995772

Scopus Document Identifier

  • 84959237127

Digital Object Identifier (DOI)

  • 10.1001/jamaoncol.2015.2151

PubMed ID

  • 26791846

Additional Document Info

volume

  • 30

issue

  • 1